Trial Profile
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Imifoplatin (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors SciClone Pharmaceuticals
- 26 Sep 2016 According to a SciClone Pharmaceuticals media release, first patient has been treated in the phase I part of the study. The company anticipates to complete enrollment in the dose-escalation portion of the trial in early 2017.
- 20 Sep 2016 New trial record